Ember Financial Statements From 2010 to 2026
| EMBT Stock | USD 0.0001 0.00 0.00% |
Check Ember Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ember Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Ember financial statements analysis is a perfect complement when working with Ember Therapeutics Valuation or Volatility modules.
Ember |
Ember Therapeutics Company Price To Earning Analysis
Ember Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Ember Therapeutics Price To Earning | 26.61 X |
Most of Ember Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ember Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Ember Therapeutics has a Price To Earning of 26.609 times. This is 2.98% higher than that of the sector and notably higher than that of the Price To Earning industry. The price to earning for all United States stocks is 7.35% higher than that of the company.
Ember Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ember Therapeutics's current stock value. Our valuation model uses many indicators to compare Ember Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ember Therapeutics competition to find correlations between indicators driving Ember Therapeutics's intrinsic value. More Info.Ember Therapeutics is rated # 5 in current valuation category among its peers. It is rated below average in shares outstanding category among its peers creating about 3.33 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ember Therapeutics' earnings, one of the primary drivers of an investment's value.About Ember Therapeutics Financial Statements
Ember Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Ember Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Ember Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ember Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York. Ember Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ember Pink Sheet Analysis
When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.